# HSV529 Vaccine in HSV-2 Seropositive Adults

> **NCT02571166** · PHASE1 · COMPLETED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 10 (actual)

## Conditions studied

- Herpes Simplex Virus 2

## Interventions

- **BIOLOGICAL:** HSV529
- **DRUG:** Valacyclovir

## Key facts

- **NCT ID:** NCT02571166
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2018-12-01
- **Final completion:** 2018-12-01
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2019-01-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02571166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02571166, "HSV529 Vaccine in HSV-2 Seropositive Adults". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02571166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*